Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

Table 4 Pathological responses and nodal status after completion of chemotherapy

Pathological response	Grade	Weekly docetaxel (n = 41)		3-weekly docetaxel (n = 41)		P-value
		No.	%	No.	%
Primary tumour	1	10	24	7	17	0.90
	2	5	12	4	10
	3	11	27	11	27
	4	7	17	8	19
	5	8	20	11	27
Lymph node
Negative		25	61	28	68	0.86
Positive	1	8	19	8	20
	2	2	5	0	0
	3	2	5	2	5
	4	0	0	0	0
	5	2	5	2	5
	NA	2	5	1	2

ISSN: 1471-2407